CD274 and head and neck squamous cell carcinoma: Therefore, based on the results of the KESTREL trial, we aimed to determine whether these regimens were cost-effective for R/M HNSCC treatment in the United States, either in the total population or in subgroups with high PD-L1 expression (TC ≥ 50% or IC ≥ 25%).